BDO Wealth Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$87.7K Hold
35,234
0.01% 358
2023
Q1
$94.4K Hold
35,234
0.01% 334
2022
Q4
$191K Hold
35,234
0.02% 265
2022
Q3
$440K Hold
35,234
0.06% 178
2022
Q2
$174K Hold
35,234
0.02% 267
2022
Q1
$268K Hold
35,234
0.03% 234
2021
Q4
$360K Hold
35,234
0.04% 215
2021
Q3
$473K Hold
35,234
0.05% 187
2021
Q2
$773K Hold
35,234
0.09% 156
2021
Q1
$848K Hold
35,234
0.1% 142
2020
Q4
$634K Hold
35,234
0.09% 133
2020
Q3
$407K Hold
35,234
0.07% 148
2020
Q2
$855K Hold
35,234
0.15% 104
2020
Q1
$388K Hold
35,234
0.08% 138
2019
Q4
$931K Hold
35,234
0.24% 77
2019
Q3
$803K Hold
35,234
0.21% 91
2019
Q2
$1.08M Hold
35,234
0.29% 69
2019
Q1
$585K Buy
+35,234
New +$668K 0.17% 101

Other funds holding GTHX

BDO Wealth Advisors's GTHX Position: Q2 2023 in Review

BDO Wealth Advisors held its G1 Therapeutics, Inc. Common Stock (GTHX) position steady in Q2 2023 at 35,234 shares worth $87.7K. The position accounts for 0.01% of the portfolio, ranked #358.

BDO Wealth Advisors first reported a position in GTHX in Q1 2019 and has held it in 18 quarters since. The position peaked at $1.08M in Q2 2019. 80 funds tracked by Wall St. Rank hold GTHX as of Q2 2023.

  • BDO Wealth Advisors held 35,234 shares of G1 Therapeutics, Inc. Common Stock worth $87.7K as of Q2 2023.
  • BDO Wealth Advisors left its G1 Therapeutics, Inc. Common Stock share count unchanged in Q2 2023.
  • G1 Therapeutics, Inc. Common Stock made up 0.01% of BDO Wealth Advisors's portfolio in Q2 2023, its #358 holding.
  • BDO Wealth Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2019 and has held it in 18 quarters since.
  • BDO Wealth Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $1.08M in Q2 2019.
  • 80 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2023.

Based on BDO Wealth Advisors's 13F filing for Q2 2023, filed 1 Aug 2023.